NR3C2 and Duchenne muscular dystrophy: Lastly, in the RCT by Raman et al. [37], involving 42 US participants with DMD (median age: 15 years, inter-quartile range [IQR] not reported), those treated with mineralocorticoid receptor antagonists (eplerenone) (initiated at a LVEF > 45%) were found to have significantly lower decline in LVEF after 12 months of follow-up (median change from baseline: -1.8% [treated] vs. -3.7% [untreated], p = 0.032).